Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Rhythm Biosciences Ltd
ASX:RHY

Watchlist Manager
Rhythm Biosciences Ltd Logo
Rhythm Biosciences Ltd
ASX:RHY
Watchlist
Price: 0.22 AUD 25.71% Market Closed
Market Cap: AU$71.7m
Write Note Create Alert Ask AI

Relative Value

The Relative Value of one RHY stock under the Base Case scenario is 0.02 AUD. Compared to the current market price of 0.22 AUD, Rhythm Biosciences Ltd is Overvalued by 91%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RHY Relative Value
Base Case
0.02 AUD
Overvaluation 91%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

P/S
View Details
P/E
View Details
P/OCF
View Details
P/FCFE
View Details
P/B
View Details
EV/S
View Details
EV/GP
View Details
EV/EBITDA
View Details
EV/EBIT
View Details
EV/OCF
View Details
EV/FCFF
View Details
EV/IC
View Details

Multiples Across Competitors

RHY Competitors Multiples
Rhythm Biosciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Rhythm Biosciences Ltd
ASX:RHY
71.7m AUD 21.6 -18.7 -19.5 -19.5
US
CVS Health Corp
NYSE:CVS
95.7B USD 0.2 208.6 13.8 13.8
US
Cigna Group
XMUN:CGN
61.7B EUR 0.3 11.8 7.6 9.7
US
Cigna Corp
NYSE:CI
72.6B USD 0.3 12.1 0 0
DE
Fresenius SE & Co KGaA
XETRA:FRE
27.5B EUR 1.2 23.7 10.4 15.9
DE
Fresenius Medical Care AG
XMUN:FME
23.6B EUR 1.2 32.7 10.3 22.1
US
Laboratory Corporation of America Holdings
NYSE:LH
23B USD 1.7 26.9 14.4 20.2
US
Quest Diagnostics Inc
NYSE:DGX
20.9B USD 2 22.1 12.1 16.3
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.7B EUR 0.6 16.1 6.4 13.7
US
Guardant Health Inc
NASDAQ:GH
12.9B USD 14.6 -33.1 -34.9 -31.7
US
DaVita Inc
NYSE:DVA
10.3B USD 0.8 13.2 7.4 10.1
P/E Multiple
Earnings Growth PEG
AU
Rhythm Biosciences Ltd
ASX:RHY
Average P/E: 40.8
Negative Multiple: -18.7 		N/A N/A
US
CVS Health Corp
NYSE:CVS
208.6
32%
6.5
US
C
Cigna Group
XMUN:CGN
11.8
39%
0.3
US
Cigna Corp
NYSE:CI
12.1
39%
0.3
DE
Fresenius SE & Co KGaA
XETRA:FRE
23.7
71%
0.3
DE
Fresenius Medical Care AG
XMUN:FME
32.7
37%
0.9
US
Laboratory Corporation of America Holdings
NYSE:LH
26.9
30%
0.9
US
Quest Diagnostics Inc
NYSE:DGX
22.1
14%
1.6
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
16.1
37%
0.4
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -33.1 N/A N/A
US
DaVita Inc
NYSE:DVA
13.2
4%
3.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Rhythm Biosciences Ltd
ASX:RHY
Average EV/EBITDA: 10.3
Negative Multiple: -19.5 		N/A N/A
US
CVS Health Corp
NYSE:CVS
13.8
25%
0.6
US
C
Cigna Group
XMUN:CGN
7.6
4%
1.9
US
Cigna Corp
NYSE:CI
Not Available N/A N/A
DE
Fresenius SE & Co KGaA
XETRA:FRE
10.4
14%
0.7
DE
Fresenius Medical Care AG
XMUN:FME
10.3
10%
1
US
Laboratory Corporation of America Holdings
NYSE:LH
14.4
16%
0.9
US
Quest Diagnostics Inc
NYSE:DGX
12.1
8%
1.5
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
6.4
10%
0.6
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -34.9 N/A N/A
US
DaVita Inc
NYSE:DVA
7.4
4%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Rhythm Biosciences Ltd
ASX:RHY
Average EV/EBIT: 15.2
Negative Multiple: -19.5 		N/A N/A
US
CVS Health Corp
NYSE:CVS
13.8
19%
0.7
US
C
Cigna Group
XMUN:CGN
9.7
5%
1.9
US
Cigna Corp
NYSE:CI
Not Available N/A N/A
DE
Fresenius SE & Co KGaA
XETRA:FRE
15.9
20%
0.8
DE
Fresenius Medical Care AG
XMUN:FME
22.1
25%
0.9
US
Laboratory Corporation of America Holdings
NYSE:LH
20.2
27%
0.7
US
Quest Diagnostics Inc
NYSE:DGX
16.3
11%
1.5
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13.7
25%
0.5
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -31.7 N/A N/A
US
DaVita Inc
NYSE:DVA
10.1
4%
2.5

See Also

Summary
RHY intrinsic value, competitors valuation, and company profile.
DCF Valuation
RHY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RHY stock valuation using valuation multiples.
Wall Street Estimates
RHY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RHY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 315,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.